Discover Pin-point™, a first-generation base editing technology that we have licensed from Rutgers, a system we’ve since developed further to accelerate therapeutic development. Read the popular article now and see more of our recent advancements in the base editing space.
New advances in the use of base editing technology for treating sickle cell disease highlight the therapeutic promise of base editing in cell and gene therapy.
Accell siRNA has been widely literature-cited for gene silencing in primary immune cells, which have historically been difficult to transfect. Learn more here.
Guidelines for making the most out of your CRISPR experiment
Now Horizon's popular reference standards have been exome sequenced for higher confidence and expanded applications. Read on to find out how this new level of product information will support your diagnostics pipeline.
Learn how precise control of Cas9 expression helps reveal the function of essential genes.
Once you have carried out your gene editing experiment, how will you monitor the result?
Learn how ON-TARGETplus siRNA from Dharmacon ensures target specificity while avoiding off-target effects to give you confidence in your RNAi studies.
Ready for gene editing? Get started with our All-in-one lentiviral system, an easy to use, single reagent for CRISPRko.
A proof-of-concept study where CRISPR-Cas9 reagents and guides to 3 genes were added to the same cell population and then a representative subset of clonal cell lines were analyzed for multiplexed gene editing efficiency.